Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption


Autoria(s): Kalmar, E. M. N.; Sanabani, S. S.; Costa, A. Charlys da; Ferreira, S.; Barreto, C. C.; Chen, S.; Sabino, E. C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

Most of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather than in the setting of treatment interruption (TI). In this study, we analysed reasons given for TI and resistance mutations occurring in 150 HIV-1-infected patients who underwent TI. Of the patients analysed, 110 (73.3%) experienced TI following medical advice, while the remaining patients stopped antiretroviral therapy (ART) of their own accord. The main justifications for TI were: ARV-related toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI correlated with drug resistance (P < 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to this problem when the use of ARVs is interrupted.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2002/04016-4]

Identificador

INTERNATIONAL JOURNAL OF STD & AIDS, LONDON, v. 23, n. 2, pp. 120-125, FEB, 2012

0956-4624

http://www.producao.usp.br/handle/BDPI/42009

10.1258/ijsa.2011.011124

http://dx.doi.org/10.1258/ijsa.2011.011124

Idioma(s)

eng

Publicador

ROYAL SOC MEDICINE PRESS LTD

LONDON

Relação

INTERNATIONAL JOURNAL OF STD & AIDS

Direitos

restrictedAccess

Copyright ROYAL SOC MEDICINE PRESS LTD

Palavras-Chave #HUMAN IMMUNODEFICIENCY VIRUS #HIV #ANTIRETROVIRAL THERAPY #RESISTANCE #TREATMENT INTERRUPTION #IMMUNODEFICIENCY-VIRUS TYPE-1 #BLOOD MONONUCLEAR-CELLS #REVERSE-TRANSCRIPTASE #INFECTED INDIVIDUALS #PROTEASE INHIBITORS #EXPERIENCED PATIENTS #RANDOMIZED-TRIAL #TREATMENT-NAIVE #MUTATIONS #PLASMA #IMMUNOLOGY #INFECTIOUS DISEASES
Tipo

article

original article

publishedVersion